Jessica C Hassel

List of Publications by Year in Descending Order

161 papers	28,994 citations	42 h-index	170 g-index
177 ext. papers	35,157 ext. citations	8.4 avg, IF	6.34 L-index

#	Paper	IF	Citations
161	Targeted Therapy for Melanomas Without BRAF V600 Mutations.. *Current Treatment Options in Oncology*, **2022**, 1	5.4	1
160	MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.. *European Journal of Cancer*, **2022**, 166, 24-32	7.5	1
159	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.. *European Journal of Cancer*, **2022**, 166, 60-72	7.5	0
158	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA).. *OncoImmunology*, **2022**, 11, 2066609	7.2	3
157	Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy.. *Strahlentherapie Und Onkologie*, **2022**, 1	4.3	1
156	546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) **2021**, 9, A576-A576		1
155	Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.. *Life*, **2021**, 11,	3	1
154	549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion **2021**, 9, A579-A579		0
153	538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp **2021**, 9, A568-A568		1
152	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. *European Journal of Cancer*, **2021**, 162, 22-33	7.5	2
151	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy **2021**, 9,		4
150	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. *Frontiers in Oncology*, **2021**, 11, 765608	5.3	1
149	Interim [F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1932-1943	8.8	9
148	Quantitative Dynamic F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. *Cancers*, **2021**, 13,	6.6	4
147	Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. *Life*, **2021**, 11,	3	2
146	Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. *Trials*, **2021**, 22, 294	2.8	0
145	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. *European Journal of Cancer*, **2021**, 147, 170-181	7.5	11

144	Multiple alopecic patches in the hairy scalp area of a 28-year-old female patient. *JDDG - Journal of the German Society of Dermatology*, **2021**, 19, 1222-1224	1.2	
143	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 655-664	21.7	9
142	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. *European Journal of Cancer*, **2021**, 149, 37-48	7.5	3
141	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. *European Journal of Cancer*, **2021**, 149, 1-10	7.5	4
140	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. *Frontiers in Oncology* , **2021**, 11, 672172	5.3	1
139	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. *Cancers*, **2021**, 13,	6.6	3
138	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. *European Journal of Cancer*, **2021**, 148, 61-75	7.5	5
137	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 643-654	21.7	58
136	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. *European Journal of Cancer*, **2021**, 152, 139-154	7.5	4
135	Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. *European Journal of Cancer*, **2021**, 152, 41-48	7.5	5
134	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study **2021**, 9,		9
133	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. *Cancers*, **2021**, 13,	6.6	2
132	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 1763-1771	4.9	0
131	Four cases of erysipelas-like inflammation in patients with metastatic melanoma treated with checkpoint inhibitors. *JDDG - Journal of the German Society of Dermatology*, **2021**, 19, 598-602	1.2	0
130	Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. *OncoImmunology*, **2021**, 10, 1926762	7.2	9
129	Generalized perforating granuloma annulare: a case report. *JDDG - Journal of the German Society of Dermatology*, **2021**, 19, 585-587	1.2	1
128	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma **2021**,		5
127	Assessment of early metabolic progression in melanoma patients under immunotherapy: an F-FDG PET/CT study. *EJNMMI Research*, **2021**, 11, 89	3.6	4

126	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. *New England Journal of Medicine*, **2021**, 385, 1196-1206	59.2	63
125	Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab. *Immunotherapy*, **2021**, 13, 1079-1083	3.8	2
124	Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	0
123	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet, The*, **2020**, 395, 1558-1568	40	100
122	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
121	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update. *JDDG - Journal of the German Society of Dermatology*, **2020**, 18, 582-609	1.2	11
120	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. *American Journal of Hematology*, **2020**, 95, 1158	7.1	12
119	"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. *Scientific Reports*, **2020**, 10, 2141	4.9	26
118	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. *Clinical Cancer Research*, **2020**, 26, 2257-2267	12.9	18
117	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1823-1832	7.4	6
116	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients **2020**, 8,		27
115	Skin Care During and After Radiotherapy and Anticancer Treatment **2020**, 1-16		
114	Cerebral metastases of a dermatofibrosarcoma protuberans. *JDDG - Journal of the German Society of Dermatology*, **2020**, 18, 143-145	1.2	
113	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, **2020**, 182, 1252-1270.e34	56.2	84
112	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. *Journal of Clinical Oncology*, **2020**, 38, 3937-3946	2.2	39
111	Positron Emission Tomography in Merkel Cell Carcinoma. *Cancers*, **2020**, 12,	6.6	5
110	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients **2020**, 8,		19
109	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. *European Journal of Cancer*, **2020**, 138, 125-132	7.5	17

108	Melanoma brain metastases - Interdisciplinary management recommendations 2020. *Cancer Treatment Reviews*, **2020**, 89, 102083	14.4	25
107	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. *Nature*, **2020**, 585, 107-112	50.4	195
106	Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. *Frontiers in Oncology*, **2020**, 10, 592796	5.3	4
105	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. *Future Oncology*, **2020**, 16, 2089-2099	3.6	1
104	Human innate immune cell crosstalk induces melanoma cell senescence. *OncoImmunology*, **2020**, 9, 1808424	7.2	0
103	Pleomorphic dermal sarcoma with cerebral metastasis. *JDDG - Journal of the German Society of Dermatology*, **2020**, 18, 886-888	1.2	
102	The Outcome of TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic Growth Capacity between T-Cell Clones. *Clinical Cancer Research*, **2020**, 26, 4289-4301	12.9	17
101	Targeted Therapy in Advanced Melanoma With Rare Mutations. *Journal of Clinical Oncology*, **2019**, 37, 3142-3151	2.2	43
100	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600´E/K-mutant advanced or metastatic melanoma. *European Journal of Cancer*, **2019**, 109, 61-69	7.5	18
99	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. *ESMO Open*, **2019**, 4, e000491	6	71
98	Prophylaxis and Management of Skin Toxicities. *Breast Care*, **2019**, 14, 72-77	2.4	8
97	Susceptibility-weighted imaging in malignant melanoma brain metastasis. *Journal of Magnetic Resonance Imaging*, **2019**, 50, 1251-1259	5.6	5
96	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. *European Journal of Cancer*, **2019**, 110, 11-20	7.5	33
95	Clinical significance of signs of autoimmune colitis in F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. *Immunotherapy*, **2019**, 11, 667-676	3.8	23
94	5-year results for pembrolizumab treatment of advanced melanoma. *Lancet Oncology, The*, **2019**, 20, 1187-1189	21.7	3
93	Immunotherapies for the Treatment of Uveal Melanoma-History and Future. *Cancers*, **2019**, 11,	6.6	34
92	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study **2019**, 7, 299		52
91	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. *Cancer Immunology, Immunotherapy*, **2019**, 68, 765-772	7.4	23

90	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. *Melanoma Research*, **2019**, 29, 178-186	3.3	27
89	Can benign lymphoid tissue changes in F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. *Cancer Immunology, Immunotherapy*, **2019**, 68, 297-303	7.4	30
88	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. *JAMA Oncology*, **2019**, 5, 187-194	13.4	173
87	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 510-520	21.7	123
86	Rituximab as a therapeutic option for patients with advanced melanoma. *Cancer Immunology, Immunotherapy*, **2018**, 67, 917-924	7.4	15
85	The role of interim F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1289-1296	8.8	64
84	STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-□*Melanoma Research*, **2018**, 28, 204-210	3.3	6
83	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. *European Journal of Cancer* , **2018**, 96, 34-43	7.5	59
82	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. *British Journal of Cancer*, **2018**, 118, 785-792	8.7	25
81	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. *Cancer Medicine*, **2018**, 7, 95-104	4.8	14
80	Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. *Cancer Immunology, Immunotherapy*, **2018**, 67, 175-182	7.4	68
79	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. *Frontiers in Immunology*, **2018**, 9, 1474	8.4	126
78	Longitudinal studies of the F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. *Cancer Immunology, Immunotherapy*, **2018**, 67, 1261-1270	7.4	19
77	Sensitivity of different MRI sequences in the early detection of melanoma brain metastases. *PLoS ONE*, **2018**, 13, e0193946	3.7	21
76	Absolute number of new lesions on F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 376-383	8.8	105
75	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. *Journal of Clinical Oncology*, **2018**, 36, 383-390	2.2	273
74	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. *Diagnostics*, **2018**, 8,	3.8	20
73	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. *Pathology*, **2018**, 50, 703-710	1.6	17

72	Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. *European Journal of Cancer*, **2018**, 104, 239-242	7.5	27
71	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2018**, 4, 1721-1728	13.4	893
70	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. *European Journal of Cancer*, **2017**, 75, 24-32	7.5	118
69	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. *Cancer Treatment Reviews*, **2017**, 57, 36-49	14.4	185
68	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). *OncoImmunology*, **2017**, 6, e1326440	7.2	51
67	Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. *Journal of Immunotherapy*, **2017**, 40, 282-285	5	25
66	PD-1 Antibody-induced Guillain-Barr Syndrome in a Patient with Metastatic Melanoma. *Acta Dermato-Venereologica*, **2017**, 97, 395-396	2.2	32
65	Bone Formation in Cutaneous Nodules on the Leg: A Quiz. Osteogenic cutaneous metastases in malignant melanoma. *Acta Dermato-Venereologica*, **2017**, 97, 1263-1264	2.2	
64	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2017**, 35, 3815-3822	2.2	160
63	Liquid Biopsy: Value for Melanoma Therapy. *Oncology Research and Treatment*, **2017**, 40, 430-434	2.8	8
62	Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. *Melanoma Research*, **2017**, 27, 321-325	3.3	35
61	Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?. *Cancer Medicine*, **2017**, 6, 1581-1586	4.8	19
60	The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. *Journal of Investigative Dermatology*, **2017**, 137, 261-264	4.3	9
59	Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. *Hellenic Journal of Nuclear Medicine*, **2017**, 20, 251-253	0.6	1
58	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. *EJNMMI Research*, **2016**, 6, 61	3.6	23
57	Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 662-81	1.2	33
56	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. *Nature*, **2016**, 534, 396-401	50.4	819
55	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. *Clinical Cancer Research*, **2016**, 22, 2908-18	12.9	372

54	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. *JAMA Oncology*, **2016**, 2, 234-40	13.4	408
53	Vemurafenib and ipilimumab: A promising combination? Results of a case series. *OncoImmunology*, **2016**, 5, e1101207	7.2	13
52	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. *Cancer Treatment Reviews*, **2016**, 45, 7-18	14.4	264
51	Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. *Annals of Oncology*, **2016**, 27, 1353-4	10.3	11
50	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. *Oncotarget*, **2016**, 7, 36130-36137	3.3	8
49	Limitations of Ber-EP4 for distinction of Bowen disease from basal cell carcinoma. *Journal of Cutaneous Pathology*, **2016**, 43, 367-71	1.7	3
48	Raster-scanned intensity-controlled carbon ion therapy for mucosal melanoma of the paranasal sinus. *Head and Neck*, **2016**, 38 Suppl 1, E1445-51	4.2	11
47	18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. *Clinical Nuclear Medicine*, **2016**, 41, 156-8	1.7	5
46	Exanthematous cutaneous spread of metastatic urothelial carcinoma in a 69-year-old man. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 1300-1302	1.2	
45	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. *Clinical Cancer Research*, **2016**, 22, 5487-5496	12.9	373
44	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. *European Journal of Cancer*, **2016**, 60, 210-25	7.5	391
43	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. *European Journal of Cancer*, **2016**, 60, 190-209	7.5	412
42	Ipilimumab plus nivolumab for advanced melanoma. *Lancet Oncology, The*, **2016**, 17, 1471-1472	21.7	18
41	Immunotherapy of Melanoma. *Oncology Research and Treatment*, **2016**, 39, 369-76	2.8	10
40	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *New England Journal of Medicine*, **2016**, 375, 1845-1855	59.2	870
39	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. *OncoImmunology*, **2016**, 5, e1240859	7.2	51
38	Nivolumab in previously untreated melanoma without BRAF mutation. *New England Journal of Medicine*, **2015**, 372, 320-30	59.2	3809
37	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 386-96	8.8	107

36	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 375-84	21.7	1881
35	Solitary, well-circumscribed, depressed palmar lesion. *American Journal of Dermatopathology*, **2015**, 37, 166	0.9	1
34	Primary melanoma of the prostate: case report and review of the literature. *BMC Urology*, **2015**, 15, 68	2.2	10
33	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science*, **2015**, 350, 207-211	33.3	1583
32	Two cases of intralymphatic histiocytosis following hip replacement. *JDDG - Journal of the German Society of Dermatology*, **2015**, 13, 700-2	1.2	2
31	In vivo visualization of mesoscopic anatomy of healthy and pathological lymph nodes using 7T MRI: a feasibility study. *Journal of Magnetic Resonance Imaging*, **2015**, 41, 1405-12	5.6	4
30	Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. *Future Oncology*, **2015**, 11, 591-606	3.6	14
29	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. *Cell Research*, **2015**, 25, 208-24	24.7	126
28	RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma. *Journal of Investigative Dermatology*, **2015**, 135, 636-639	4.3	5
27	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. *European Journal of Cancer*, **2014**, 50, 406-10	7.5	21
26	Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. *Strahlentherapie Und Onkologie*, **2014**, 190, 1080-1	4.3	13
25	Comparison of molecular abnormalities in vulvar and vaginal melanomas. *Modern Pathology*, **2014**, 27, 1386-93	9.8	55
24	Axillary accessory breast tissue--case report and review of literature. *JDDG - Journal of the German Society of Dermatology*, **2014**, 12, 499-500	1.2	2
23	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discovery*, **2014**, 4, 94-109	24.4	626
22	Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. *Journal of Nuclear Medicine*, **2014**, 55, 9-14	8.9	41
21	Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. *PLoS ONE*, **2014**, 9, e95723	3.7	11
20	Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. *Journal of Investigative Dermatology*, **2013**, 133, 1034-42	4.3	27
19	Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST. *Academic Radiology*, **2013**, 20, 423-9	4.3	4

18	Varicella-like cutaneous toxoplasmosis in a patient with aplastic anemia. *Journal of Clinical Microbiology*, **2013**, 51, 1341-4	9.7	3
17	Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma. *Experimental Dermatology*, **2013**, 22, 757-9	4	8
16	Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. *Internal Medicine*, **2013**, 52, 151-2	1.1	1
15	Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". *JDDG - Journal of the German Society of Dermatology*, **2013**, 11 Suppl 6, 1-116, 1-126	1.2	79
14	Compression Treatment of Ear Keloids by a Modified Oyster Splint Technique **2013**, 499-505		
13	Improved survival with MEK inhibition in BRAF-mutated melanoma. *New England Journal of Medicine*, **2012**, 367, 107-14	59.2	1634
12	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. *Journal of Clinical Oncology*, **2012**, 30, LBA8509-LBA8509	2.2	10
11	Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. *Journal of Clinical Oncology*, **2012**, 30, e19031-e19031	2.2	
10	Psychosomatic or allergic symptoms? High levels for somatization in patients with drug intolerance. *Journal of Dermatology*, **2011**, 38, 959-65	1.6	19
9	Promising results from a pilot study on compression treatment of ear keloids. *Journal of Cutaneous Medicine and Surgery*, **2011**, 15, 130-6	1.6	14
8	Phenol chemical matricectomy is less painful, with shorter recovery times but higher recurrence rates, than surgical matricectomy: a patient Q view. *Dermatologic Surgery*, **2010**, 36, 1294-9	1.7	10
7	Improved survival with ipilimumab in patients with metastatic melanoma. *New England Journal of Medicine*, **2010**, 363, 711-23	59.2	10591
6	Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. *Clinical Cancer Research*, **2009**, 15, 5208-15	12.9	147
5	Predicting tooth color from facial features and gender: results from a white elderly cohort. *Journal of Prosthetic Dentistry*, **2008**, 99, 101-6	4	20
4	STAT5 contributes to antiapoptosis in melanoma. *Melanoma Research*, **2008**, 18, 378-85	3.3	26
3	Treatment of ear keloids by compression, using a modified oyster-splint technique. *Dermatologic Surgery*, **2007**, 33, 208-12	1.7	13
2	STAT5 contributes to interferon resistance of melanoma cells. *Current Biology*, **2005**, 15, 1629-39	6.3	52
1	Serological immunomarkers in cutaneous T cell lymphoma. *Dermatology*, **2004**, 209, 296-300	4.4	24